8-K: Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
10-Q: Quarterly report
10-K/A: Annual report (Amendment)
10-K: FY2024 Annual Report
10-Q: Q2 2024 Earnings Report
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
10-Q: Q1 2024 Earnings Report
TenX Keane Acquisition Announces Contribution to Trust Account in Connection With Extension Amendment Proposal
TenX Keane Acquisition Extends Deadline for Initial Business Combination
TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination
TenX Keane Acquisition Corp.'s (NASDAQ:TENKU) Lock-Up Period Will Expire on April 12th
News On TenX Keane Acquisition (TENKU) Now Under TENK
Reported Late Tuesday, TenX Keane Acquisition Announces The Separate Trading Of Its Ordinary Shares And Rights Commencing On December 8, 2022
TenX Keane Acquisition Announces the Separate Trading of Its Ordinary Shares and Rights Commencing on December 8, 2022
TenX Keane Acquisition Announces Closing of $66 Million Initial Public Offering, Including Partial Exercise of Underwriter’s Over-Allotment Option
TenX Keane Acquisition Announces Pricing of $60 Million Initial Public Offering
TenX Keane Acquisition Announces Pricing of $60M Initial Public Offering